Context Therapeutics Inc. (CNTX)
(Delayed Data from NSDQ)
$2.48 USD
-0.02 (-0.80%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.48 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Context Therapeutics Inc. [CNTX]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
CT-95 Acquisition Diversifies Context''s T Cell Engager Pipeline Against Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
1Q24 Recap: CTIM-76 Phase 1 First Patient Dosing Expected in Mid-2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
CTIM-76 Receives IND Clearance; Private Placement to Extend Cash Runway
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
4Q23 Recap: CTIM-76 Phase 1 to Focus on Gynecologic and Testicular Cancers
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Q3 2023 Financial Update; IND Application Filing and Phase 1 Clinical Trial Commencement Anticipated Next Year
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
3Q23 Recap: We Expect CTIM-76 Phase 1 Initiation in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Unveils Encouraging Pre-Clinical Outcomes and Reports Enhanced Therapeutic Potential of CTIM-76 Over First-Gen CLDN6 Therapies
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
CTIM-76 Could Be Differentiated Among the CLDN6 Targeted Competitors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Additional CLDN6 Data at ESMO Provide More Proof of Target Though Toxicity Still a Question
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Substantial Cash Reserves Support the Progress of CTIM-76 Toward IND Filing, Anticipated by Q1 2024
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
2Q23 Recap: CTIM-76 IND Filing Is on Track for 1Q24; CLDN6 Is Gaining Target Validation
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Competitors'' CLDN6 Data at ASCO Continue to Validate CLDN6 as a Viable Target in Solid Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Management to Highlight Upcoming Expectations Around Claudin-6 at ASCO Annual Meeting
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
ASCO Meeting Set to Provide Robust Validation for Claudin-6 as a Novel Cancer Target
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
1Q23 Recap: New CLDN6 Competitor Data at ASCO Could Provide More Validation to the Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
FY23 focus squarely on CTIM-76
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
R&D webinar highlights CTIM-76?s potential
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Updated Preclinical CTIM-76 Data Highlight CLDN6 Specificity and Wide Therapeutic Window; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
Adjusting Resource Allocation Strategy Towards Attractive Early-Stage Asset
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Context Therapeutics Inc.
Industry: Medical - Drugs
4Q22 Take: Lead Asset ONA-XR Discontinued With Focus Now on CTIM-76; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E